Angiotensin II receptor antagonists

Details

Serval ID
serval:BIB_50C4A9A0887B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Angiotensin II receptor antagonists
Journal
Lancet
Author(s)
Burnier  M., Brunner  H. R.
ISSN
0140-6736 (Print)
Publication state
Published
Issued date
02/2000
Volume
355
Number
9204
Pages
637-45
Notes
Journal Article
Review --- Old month value: Feb 19
Abstract
Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of cardiovascular disease with specific pharmacological probes. Oral activity, achieved by shortening the original peptide structures, transformed the probes into therapeutic agents, the angiotensin-converting enzyme (ACE) inhibitors. However, ACE is a non-specific target for blocking the renin-angiotensin enzymatic cascade. The availability of orally active drugs turned ACE inhibition into a therapeutic breakthrough but more specific blockade always seemed desirable. This goal has now been achieved with the orally active angiotensin II receptor antagonists; six are on the market and more are under development. This new class of drugs is equal in efficacy to ACE inhibitors, at least in hypertensive patients. Trials now underway will demonstrate whether angiotensin II receptor antagonists can prevent target-organ damage and reduce cardiovascular morbidity and mortality. If they do, these compounds might one day replace ACE inhibitors.
Keywords
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use Animals Antihypertensive Agents/*therapeutic use Clinical Trials Dogs Humans Hypertension/*drug therapy Receptors, Angiotensin/*antagonists & inhibitors Renin-Angiotensin System/drug effects Safety
Pubmed
Web of science
Create date
25/01/2008 12:56
Last modification date
20/08/2019 14:06
Usage data